Valneva Announces Availability of Documentation for its Annual General Meeting
Globe Newswire (Thu, 4-Jun 1:00 AM ET)
Valneva to Participate at U.S. and European Investor Conferences in June
Globe Newswire (Thu, 28-May 11:45 AM ET)
Valneva Reports First Quarter 2026 Financial Results and Provides Corporate Updates
Globe Newswire (Wed, 13-May 1:00 AM ET)
Valneva to Report First Quarter 2026 Consolidated Financial Results on May 13, 2026
Globe Newswire (Tue, 5-May 11:45 AM ET)
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Valneva SE - VALN
PRNewswire (Thu, 30-Apr 10:40 PM ET)
Valneva Announces the Successful Completion of an EUR 84 million Reserved Offering
Globe Newswire (Thu, 30-Apr 1:15 AM ET)
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims on Behalf of Investors of Valneva SE - VALN
Globe Newswire (Tue, 21-Apr 5:21 PM ET)
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Valneva SE - VALN
PRNewswire (Thu, 9-Apr 10:01 AM ET)
Market Chameleon (Mon, 23-Mar 3:54 AM ET)
Valneva SE is a vaccine company focused on developing life-saving vaccines. Its portfolio includes three vaccines for travelers. The segments of the group are Commercialized vaccines which relate to marketed vaccines, the group's vaccines IXIARO/JESPECT, DUKORAL, IXCHIQ; Covid includes development, manufacturing, & distribution related to the COVID-19 vaccine, Vaccine candidates which relate to research and development programs to generate new approvable products to generate future cash flows from product sales through partnering with pharmaceutical companies; & Technologies and services which relate to services and inventions at a commercialization stage. The company generates majority of its revenue from product sales.
Valneva Se - American Depositary Shares trades on the NASDAQ stock market under the symbol VALN.
As of June 18, 2026, VALN stock price climbed to $5.38 with 12,872 million shares trading.
VALN has a beta of 2.88, meaning it tends to be more sensitive to market movements. VALN has a correlation of 0.19 to the broad based SPY ETF.
VALN has a market cap of $510.15 million. This is considered a Small Cap stock.
Last quarter Valneva Se - American Depositary Shares reported $36 million in Revenue and -$.42 earnings per share. This fell short of revenue expectation by $-10 million and missed earnings estimates by -$.21.
In the last 3 years, VALN traded as high as $17.05 and as low as $3.62.
VALN has underperformed the market in the last year with a price return of -8.5% while the SPY ETF gained +26.2%. VALN has also underperformed the stock market ETF in the last 3 month and 2 week periods returning -51.1% and -3.6%, respectively, while the SPY returned +11.6% and -1.0%, respectively.
VALN support price is $5.14 and resistance is $5.56 (based on 1 day standard deviation move). This means that using the most recent 20 day stock volatility and applying a one standard deviation move around the stock's closing price, stastically there is a 67% probability that VALN shares will trade within this expected range on the day.